Track record · closed signal

Thermo Fisher Scientific Inc. (TMO) — closed signal from October 21, 2025

Near target Published before the outcome was known, scored automatically when the window closed on January 19, 2026 — +10.9% at the close.

Predicted vs. what happened

TMO price · publication thesis → realized outcomesplit-adjusted
$557.75 Published $635.36 Target $618.72 Window close $629.87 Peak
$549.17 – $559.16Entry zone — fair-value band
$557.75Published — price the day we called it
$635.36Target — the price the thesis aimed for
$629.87Peak — highest point inside the window, not a realized return
$618.72Window close — end-of-window price, context only

What happened

Near target

Came within reach: 92% of the predicted growth at its peak, just short of the target.

At window close
+10.9%
realized, from the publication price to the last close inside the window
Peak gain
+12.9%
peak, from the publication price — not a realized return
S&P 500, same window
+3.3%
SPY over the identical days, dividend-adjusted
Window close
$618.72
last close inside the window, ended January 19, 2026
Peak price
$629.87
peak on January 15, 2026 — not a realized return
Days to target
—

The thesis — published October 21, 2025

Predicted growth
+14%
over the measurement window
Target price
$635.36
the price the thesis aimed for
Entry zone
$549.17 – $559.16
the fair-value band we waited for
Price at publication
$557.75
published October 21, 2025
Confidence
72%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Thermo Fisher is a well-liked name in medical tools and services, and buyers have been active. A key growth area it serves, bioseparation, is expected to reach $45.1B by 2030, which supports steady demand. Buying near $550-$560 aims to join an ongoing uptrend while staying careful because mood can move faster than the numbers. We look for a steady 0-3 month climb, especially on days when trading is heavier than normal.

Primary drivers

  • Bioseparation could reach $45.1B by 2030, supporting strong long-run demand
  • Trend is firm and buying interest has been stronger than selling lately
  • The stock stays popular with investors, reinforcing steady interest
  • Near-term results are coming soon and may guide the next few months

How it played out

TMO: strong rise, target not reached

Lyra published TMO at $557.75 on 2025-10-21, looking for 14% growth over a short-term window. The thesis pointed to bioseparation demand, a firm trend, stronger buying interest than selling, steady investor interest, and near-term results that could guide the next few months.

Inside the window from 2025-10-21 to 2026-01-19, TMO rose but did not reach the $635.36 target. It peaked at $629.87 on 2026-01-15, a 12.9% gain. It ended at $618.72. The thesis mostly played out on direction and strength, but the target was missed.

What happened during the window

On October 29, 2025, Thermo Fisher announced a cash deal to buy Clario, with $8.9 billion upfront and up to $525 million in milestones. The deal was expected to close by mid-2026.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All TMO signals